Co-Aprovel 150/12.5 mg is a prescription combination medication indicated for the management of essential hypertension (high blood pressure) in adult patients. By combining two distinct pharmacological agents with complementary mechanisms of action, this formulation provides effective, dual-action blood pressure control when monotherapy is insufficient.
1. Active Ingredients and Mechanism of Action
Co-Aprovel contains two active pharmaceutical ingredients designed to lower blood pressure through different physiological pathways, ensuring enhanced efficacy and formulation safety:
Irbesartan (150 mg): Classified as an Angiotensin II Receptor Blocker (ARB). It selectively blocks the binding of angiotensin II—a potent peptide hormone that causes blood vessels to constrict—to the AT1 receptors. By inhibiting this action, irbesartan induces vasodilation (relaxation and widening of blood vessels), thereby lowering peripheral vascular resistance and reducing blood pressure.
Hydrochlorothiazide (12.5 mg): A thiazide diuretic (commonly referred to as a "water pill"). It acts on the kidneys to reduce the reabsorption of sodium and chloride ions in the distal convoluted tubule. This promotes the excretion of excess sodium, chloride, and water through urine, thereby decreasing overall blood volume and cardiac workload.
The synergistic combination of an ARB and a diuretic helps mitigate counter-regulatory mechanisms (such as fluid retention) that can sometimes occur when using an ARB alone.
2. Key Clinical Benefits and Therapeutic Value
Dual-Action Blood Pressure Reduction: Combines vasodilation and fluid reduction to achieve target blood pressure thresholds more efficiently than single-agent therapies.
Cardiovascular Risk Mitigation: Adequate and sustained control of hypertension significantly reduces the long-term risk of adverse cardiovascular events, including stroke, myocardial infarction (heart attack), and heart failure.
Improved Treatment Adherence: Combining two essential antihypertensive medications into a single, once-daily tablet simplifies complex medication regimens, supporting better patient compliance.
3. Administration and Usage Instructions
Co-Aprovel 150/12.5 mg must be taken strictly according to a qualified physician’s or cardiologist’s prescription.
Dosage & Frequency: Typically administered as one tablet once daily, with or without food. It is recommended to take the medication at the same time each day (ideally in the morning) to maintain stable drug plasma concentrations.
Swallowing: Tablets should be swallowed whole with a sufficient amount of water. Do not crush, chew, or split the tablet unless specifically advised by a healthcare professional.
Missed Dose Protocol: If a dose is missed, take it as soon as remembered. However, if it is almost time for the next scheduled dose, skip the missed dose and resume the normal dosing schedule. Do not take a double dose to make up for a forgotten tablet.
4. Safety Precautions, Warnings, and Contraindications
Because Co-Aprovel impacts blood pressure, renal function, and fluid balance, specific clinical precautions must be observed:
Pregnancy and Lactation: Co-Aprovel must not be used during pregnancy, particularly during the second and third trimesters, as acting directly on the renin-angiotensin system can cause severe injury or death to the developing fetus. Women of childbearing potential should consult their physician immediately if pregnancy is planned or confirmed.
Renal and Hepatic Function: Use with caution in patients with impaired kidney or liver function. Periodic monitoring of serum creatinine, blood urea nitrogen (BUN), and electrolyte levels (particularly potassium and sodium) is standard clinical practice.
Hypotension and Electrolyte Imbalances: Patients may experience dizziness or lightheadedness, especially during the first few days of treatment or when rising quickly from a seated or lying position (orthostatic hypotension). Hydrochlorothiazide may cause electrolyte disturbances, such as hypokalemia (low potassium) or hyponatremia.
Contraindications: Do not use in patients with known hypersensitivity to irbesartan, sulfonamide-derived drugs (such as hydrochlorothiazide), or any inactive excipients in the formulation, as well as in patients with anuria (inability to produce urine).
5. Storage and Handling
Store at room temperature, away from excessive heat, moisture, and direct sunlight (typically below 30°C).
Keep out of the sight and reach of children.
Do not use past the expiration date printed on the primary packaging.
Medication
